Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
SUPREFACT DEPOT 2 MONTHS
6.3MG · IMPLANT · CHEPLAPHARM ARZNEIMITTEL GMBH
DIN 02228955 · since Nov 1, 2024, no end estimate · Disruption of the manufacture of the drug.
Active shortage
SUPREFACT DEPOT 3 MONTHS
9.45MG · IMPLANT · CHEPLAPHARM ARZNEIMITTEL GMBH
DIN 02240749 · since Oct 24, 2023, no end estimate · Disruption of the manufacture of the drug.
reversed
SUPREFACT DEPOT 3 MONTHS
9.45MG · IMPLANT · CHEPLAPHARM ARZNEIMITTEL GMBH
DIN 02240749
Resolved
SUPREFACT
1MG · SOLUTION · CHEPLAPHARM ARZNEIMITTEL GMBH
DIN 02225166 · ended Jun 28, 2024 · Disruption of the manufacture of the drug.
reversed
SUPREFACT DEPOT 2 MONTHS
6.3MG · IMPLANT · CHEPLAPHARM ARZNEIMITTEL GMBH
DIN 02228955
Resolved
SUPREFACT DEPOT 3 MONTHS
9.45MG · IMPLANT · CHEPLAPHARM ARZNEIMITTEL GMBH
DIN 02240749 · ended May 16, 2024 · Disruption of the manufacture of the drug.
Resolved
SUPREFACT
1MG · SOLUTION · CHEPLAPHARM ARZNEIMITTEL GMBH
DIN 02225166 · ended Dec 7, 2022 · Delay in shipping of the drug.
Resolved
SUPREFACT
1MG · SOLUTION · CHEPLAPHARM ARZNEIMITTEL GMBH
DIN 02225166 · ended May 24, 2022 · Delay in shipping of the drug.
Resolved
SUPREFACT
1MG · SOLUTION · CHEPLAPHARM ARZNEIMITTEL GMBH
DIN 02225166 · ended Dec 31, 2021 · Delay in shipping of the drug.
Discontinued
SUPREFACT
100MCG · SOLUTION · CHEPLAPHARM ARZNEIMITTEL GMBH
DIN 02225158
Resolved
SUPREFACT
1MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02225166 · ended Feb 18, 2020
Resolved
SUPREFACT
1MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02225158 · ended Jun 3, 2019
Showing 12 of 13 reports. All reports are on file with Health Canada.
What's happening
Buserelin is currently affected by 2 active shortage reports filed with Health Canada by CHEPLAPHARM ARZNEIMITTEL GMBH.
The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Buserelin is classified under “HORMONES AND RELATED AGENTS” (ATC L02AE).
Recent changes
No changes recorded yet.
Common questions
What is Buserelin used for?
A hormone therapy used to treat prostate cancer and endometriosis.
When will Buserelin be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Buserelin in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.